Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy
KAUST DepartmentBiological and Environmental Sciences and Engineering (BESE) Division
Biological and Environmental Sciences and Engineering Division
MetadataShow full item record
CitationGadhoum SZ, Madhoun NY, Abuelela AF, Merzaban JS (2016) Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy. Leukemia. Available: http://dx.doi.org/10.1038/leu.2016.221.
SponsorsThis work was supported by the King Abdullah University of Science and Technology (KAUST) faculty baseline research funding program to JSM.
- Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects.
- Authors: Jhanwar-Uniyal M, Amin AG, Cooper JB, Das K, Schmidt MH, Murali R
- Issue date: 2017 May
- Bone marrow stromal cells protect acute myeloid leukemia cells from anti-CD44 therapy partly through regulating PI3K/Akt-p27(Kip1) axis.
- Authors: Chen P, Huang H, Wu J, Lu R, Wu Y, Jiang X, Yuan Q, Chen Y
- Issue date: 2015 Dec
- IκB kinase overcomes PI3K/Akt and ERK/MAPK to control FOXO3a activity in acute myeloid leukemia.
- Authors: Chapuis N, Park S, Leotoing L, Tamburini J, Verdier F, Bardet V, Green AS, Willems L, Agou F, Ifrah N, Dreyfus F, Bismuth G, Baud V, Lacombe C, Mayeux P, Bouscary D
- Issue date: 2010 Nov 18
- Amino acids activate mammalian target of rapamycin complex 2 (mTORC2) via PI3K/Akt signaling.
- Authors: Tato I, Bartrons R, Ventura F, Rosa JL
- Issue date: 2011 Feb 25
- SNS-032 inhibits mTORC1/mTORC2 activity in acute myeloid leukemia cells and has synergistic activity with perifosine against Akt.
- Authors: Meng H, Jin Y, Liu H, You L, Yang C, Yang X, Qian W
- Issue date: 2013 Feb 18